This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Tyrosine-Kinase Inhibitors for RCC: Current Recommendations and Promising New Developments

Tyrosine-Kinase Inhibitors for RCC: Current Recommendations and Promising New Developments

Format

Patient Case Simulations

Time to Complete

60 minutes

Released

December 31, 2018

Expires

December 31, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour (0.50 pharmacotherapy credit hour)

Joint Providers

Jointly provided by Postgraduate Institute for Medicine and ASiM

Commercial Supporter

This activity is supported by an independent educational grant from Pfizer, Inc.

Program Description

Renal cell carcinoma (RCC) is rare, but its prevalence is growing. In its early stages, RCC is often clinically silent, resulting in many patients presenting when their disease has become advanced or metastatic. Even in patients with clinically localized disease, there is a high risk of recurrence following nephrectomy, increasing the risk of poor outcomes. Historically, patients with RCC recurrence or advanced or metastatic disease at diagnosis had few treatment options, as chemotherapy and radiation have been largely ineffective. However, many therapeutic advances in patients with RCC have been made over the past decade, including the approval of several TKIs, which have led to improved outcomes. But, the ever-growing RCC treatment arsenal and increased recognition that RCC is a highly heterogenous disease has added to the challenge of treatment selection in patients with advanced disease. In this activity, a virtual mentor will guide you through the first- and second-line treatment selection for 2 patients with metastatic RCC, who fall at opposite ends of the prognostic spectrum. Both you and your mentor will explore the optimal use of TKIs and checkpoint inhibitors in treating each patient. You will also learn about the adverse effects associated with these treatments and how to mitigate and manage them.

Intended Audience

This activity was developed for healthcare professionals (oncologists, urologists, nurses, nurse practitioners, physician assistants, etc.) who care for patients with renal cell carcinoma. No prerequisites required.

Educational Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • OUTLINE the latest clinical research and potential role of adjuvant therapy in patients with RCC.
  • INDICATE current and future advanced RCC sequential treatment regimens with TKIs.
  • IDENTIFY recommended strategies and educational interventions to mitigate AEs in patients with RCC on TKI therapy.

Conflict Of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty

Fernando J. Kim, MD, MBA, FACS (Chair)
Chief of Urology, DHMC
Professor of Surgery/Urology
University of Colorado Denver
Associate Editor of Patient Safety in Surgery
Denver, Colorado

Dr. Kim has disclosed no relevant financial relationships.

Planners and Managers Disclosures

The PIM planners and managers have nothing to disclose. The ASiM CE LLC planners and managers have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours.

Designated for 0.50 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating and receiving CE credit for this activity. During the period December 31, 2018 through December 31, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

To obtain credit a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

Media

Internet

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue